Screener
Alkermes ALKS US — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alkermes’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 9:31 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-068925
FAQ
- What is Alkermes's US — revenue?
- Alkermes (ALKS) reported US — revenue of $343.2M in Q4 2025.
- How has Alkermes's US — revenue changed year-over-year?
- Alkermes's US — revenue decreased by 2.7% year-over-year, from $352.54M to $343.2M.
- What is the long-term trend for Alkermes's US — revenue?
- Over 4 years (2021 to 2025), Alkermes's US — revenue has grown at a 8.7% compound annual growth rate (CAGR), from $984.24M to $1.37B.
- What does US — revenue mean?
- This metric represents the total revenue generated from contracts with customers within the US geographic segment, net of any assessed taxes. It reflects the core commercial performance and market penetration of the company's pharmaceutical products in the United States. This figure is a primary indicator of the company's ability to monetize its therapeutic portfolio in its largest market.
Ask your AI about Alkermes's us — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude